Semax a synthetic heptapeptide with a decades-long track record of clinical use in Russia is being removed from the FDA's Category 2 list and scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review on July 24, 2026
These compounds are not approved by the FDA to diagnose, treat, cure, or prevent disease
Restricted to in vitro laboratory experimentation and cannot be used in clinical or investigational studies, applied in any medical or therapeutic context, or distributed for purposes outside regulated laboratory research
Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies in Childhood Phase III
Wolverine Stack The popular combination of BPC-157 and TB-500, named for the accelerated healing users report experiencing
The encapsulation of drugs into liposomes can be achieved through various methods, each tailored to the properties of the drug and the desired characteristics of the liposomal formulation
